Relevant identified uses of the substance or mixture and uses advised against Identified uses: Pharmaceutical active ingredient for treating hyperphosphatemia in chronic kidney disease patients.
First Aid Measures
General advice: Consult a physician. Show this safety data sheet to the doctor. Consult a physician. attendance.
If inhaled: If breathed in, move person into fresh air. If not breathing give artificial respiration.
In case of skin: In case of eye, rinse with plenty of water, and in case of skin, & eye contact wash with plenty of soap and water.
If swallowed: Never give anything by mouth to an unconscious person. Rinse Mouth with water.
Fire-Fighting Measures
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: Not applicable.
Explosion Hazards in Presence of Various Substances: Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media and Instructions: Wear a self-contained breathing apparatus and chemical protective clothing.
Special Remarks on Fire Hazards: Toxic fumes.
Special Remarks on Explosion Hazards: Do not inhale explosion and combustion gases. Collect contaminated fire extinguishing water separately. This must not be discharged into drains. Move undamaged containers from immediate hazard area if it can be done safely.
Exposure Controls / Personal Protection
Engineering Controls: Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants below the exposure limit.
Personal Protection: Safety glasses. Lab coat. Dust respirator. Be sure to use an approved / certified respirator or equivalent. Gloves.
Personal Protection in Case of a Large Spill: Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self-contained breathing apparatus should be used to avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this product.
Exposure Limits: TWA: 1 (mg/m3) from ACG IH Consult local authorities for acceptable exposure limits.
Physical and Chemical Properties
Appearance: Fine Powder
Odour: Odourless
Taste: Not available.
Color: Brown
Solubility: Soluble in most inorganic acids, insoluble in water
Sucroferric Oxyhydroxide (SO) is a non-calcium, iron-based, chewable phosphate binder indicated for the control of serum phosphorus levels in patients with end-stage renal disease (ESRD) receiving dialysis. There is minimal systemic iron absorption from sucroferric oxyhydroxide, and therefore the drug is associated with a low risk of iron accumulation.
Application of Sucroferric Oxyhydroxide
Phosphate Binder: Sucroferric oxyhydroxide acts as a phosphate binder, reducing the absorption of phosphate from food in the gastrointestinal tract, which is essential for CKD patients.
Chronic Kidney Disease Management: It is specifically formulated for the management of serum phosphorus levels in adult patients with CKD on hemodialysis or peritoneal dialysis.
Lower Pill Burden: Compared to other phosphate binders, sucroferric oxyhydroxide often requires a lower pill burden, meaning fewer doses are needed, which can improve patient compliance and quality of life.
Non-Calcium-Based Binder: As a non-calcium-based phosphate binder, it offers an alternative for patients who may need to avoid extra calcium intake.
Iron Reutilization: The iron in sucroferric oxyhydroxide can be partially absorbed and contribute to iron reutilization, potentially benefiting patients with CKD who often suffer from anemia.
Nutraceutical Potential: There’s potential exploration into its use as a nutraceutical component for managing dietary phosphate among populations with elevated levels, not just limited to CKD patients.
Minimal Systemic Absorption: It is designed for minimal systemic absorption, which reduces the risk of systemic iron overload – a concern with some iron-based therapies.
Synergistic Use: Sucroferric oxyhydroxide can be used alongside other treatments for CKD, such as vitamin D analogs and calcium supplements, as part of a broader management strategy.
Reduced Pill Size: It’s formulated in smaller pills compared to some other binders, which can be beneficial for patients who have difficulty swallowing.
Safety Profile: Its unique chemical structure contributes to a safety profile that is favorable for long-term use in managing chronic conditions.
If you are interested on Sucroferric Oxyhydroxide, then
